Browse studies

Find your next paid study

3,219 recruiting studies matching your filters

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or…

CancerSolid Tumor CancerAdvanced Metastatic Cancer+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Conjupro Biotherapeutics, Inc.NCT07424547

Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy

In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better …

Pediatric Patients Treated With Radiation Therapy

Estimated

~$10 – $750

Actual pay is set by the research site.

Massachusetts General HospitalNCT01696721

Observational

Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity

Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-l…

Adverse Childhood ExperienceEndothelial Function (FMD)Endothelial Injury+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of IowaNCT07244809

Observational

Theory-based Social Media Intervention for Non-medical Use of Prescription Opioids in Young Adults

Brief Summary The purposes of this study are to develop and implement a peer-led intervention program on Instagram for promoting prescription opioid use manag…

Young AdultsPast-3-month Non-medical Use of Prescription OpioidsWithout Substance Use Disorders+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of South CarolinaNCT06469749

Phase 1

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants w…

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

The LINFU® (A Noninvasive Method for Increasing Exfoliation of Pancreatic Ductal Cells Into Pancreatic Fluid) U.S. Registry for the Detection of PanIn-2, PanIn-3, and Early, Asymptomatic Pancreatic Ductal Adenocarcinoma (PDAC)

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic can…

Pancreatic Ductal Adenocarcinoma

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Adenocyte, LLCNCT04793633

Phase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VK3019, an Amylin and Calcitonin Receptor Agonist, in Overweight and Obese Adults Without Comorbidities

This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and ph…

Obese Adults

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Viking Therapeutics, Inc.NCT07846033

Phase 1

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has c…

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Northwestern UniversityNCT06410248

Phase 2

Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines an…

Prostate Adenocarcinoma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Hackensack Meridian HealthNCT06798558

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing e…

Bladder CancerUrothelial Carcinoma (UC)Hematuria+1 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Convergent Genomics, Inc.NCT07673016

Phase 3

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/…

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Ferring PharmaceuticalsNCT06545955

Phase 1

A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating pat…

Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT07214298